Paclitaxel/Cisplatin
- Generic Name
- Paclitaxel/Cisplatin
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Phase 2
- Conditions
- Resectable Esophageal CancerEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Interventions
- Radiation: Intensity-modulated radiotherapyProcedure: Esophagectomy
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Jianhua Fu
- Target Recruit Count
- 44
- Registration Number
- NCT04006041
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Phase 2
Completed
- Conditions
- Unresectable Esophageal Cancer
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 42
- Registration Number
- NCT04005170
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer
Phase 3
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 221
- Registration Number
- NCT01126216
- Locations
- 🇩🇪
Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde, Straubing, Germany
🇩🇪Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Germany
🇩🇪Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Strahlentherapie, Mönchengladbach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath